Medication info

Rasikrol Injection

Prescription medication
Ingredient · strength
Sodium Chloride›16.05mg / 1mLCalcium Chloride Hydrate›16.55mg / 1mLPotassium Chloride›74.55mg / 1mLMagnesium Chloride Hydrate›25.4mg / 1mLSodium Acetate Hydrate›200.75mg / 1mL
Manufacturer / importer
JW Pharmaceutical Corporation
Appearance
A colorless, transparent solution contained in a polypropylene container.
Packaging
20 milliliters x 50
Approval status
Active

MFDS item code 199100256 · Notified 1991.04.02

Summary

Main use
Electrolyte replacement and improved maintenance of electrolyte balance in adults receiving fluid therapy
Who uses it
Adults
Adult dosage
Add 20mL of this medicine per 1L of glucose nutritional solution or amino acid solution, and continuously infuse 2~3L per day through a central venous catheter over 24 hours at a rate of 83~125mL per hour. 2. To avoid incompatibility between phosphate and calcium, the required phosphate may be added as potassium phosphate, in an amount equivalent to 10~30mEq of potassium per 1L of parenteral nutrition solution. Visually inspect the solution for contamination before infusion.

Ingredients

Manufacturer
JW Pharmaceutical Corporation

Efficacy & effects

Electrolyte replacement and improved maintenance of electrolyte balance in adults receiving fluid therapy

View approved original text

This medication helps maintain the electrolyte balance in adult patients receiving glucose or amino acid infusions. Electrolytes are crucial for the normal functioning of the body, and this solution can replenish insufficient electrolytes. It is used to prevent various issues arising from electrolyte imbalances in the body and to stabilize health conditions.

Dosage and Administration

Adult dosage

Add 20mL of this medicine per 1L of glucose nutritional solution or amino acid solution, and continuously infuse 2~3L per day through a central venous catheter over 24 hours at a rate of 83~125mL per hour. 2. To avoid incompatibility between phosphate and calcium, the required phosphate may be added as potassium phosphate, in an amount equivalent to 10~30mEq of potassium per 1L of parenteral nutrition solution. Visually inspect the solution for contamination before infusion.

Precautions

This medication may cause precipitation when mixed with ceftazidime in intravenous calcium-containing preparations, so it should not be administered simultaneously through the same infusion device. Allergic reactions may occur while using this medication; if symptoms of hypersensitivity appear, administration should be discontinued immediately, and appropriate treatment should be obtained. Since potassium is included, there is a risk of hyperkalemia, particularly in patients with impaired renal function or heart disease, who should be monitored closely for serum potassium levels. Due to the content of sodium and chloride, electrolyte imbalances such as hypernatremia, hyperchloremia, and metabolic acidosis may occur, so patients with related diseases or high-risk factors should have their serum sodium and chloride levels and renal function regularly monitored. This medication may cause hyponatremia, so special monitoring of symptoms and blood tests is required, particularly in young children, the elderly, post-operative patients, or those taking medications that increase the risk of hyponatremia. Due to the calcium content, there is a risk of hypercalcemia; therefore, it should be avoided in patients with hypercalcemia or a history of calcium kidney stones. Intravenous administration of this medication can cause fluid overload and electrolyte imbalance, so for patients at risk of fluid overload, fluid status and electrolyte concentrations should be checked periodically during administration. It should not be administered to patients with anuria, severe cardiovascular, renal, or hepatic impairment, in pediatric patients, or to patients with hypersensitivity to this medication or its components. Caution should be exercised in patients with congestive heart failure, severe renal insufficiency, hyperkalemia, metabolic alkalosis, severe liver dysfunction, or renal impairment; professional monitoring may be necessary if needed. Electrolyte concentrations such as sodium, potassium, and calcium may change with the use of this medication, so serum electrolyte levels should be frequently monitored for abnormalities. This medication may interact with other drugs, particularly ceftazidime, drugs that induce hyperkalemia, lithium, digoxin, and corticosteroids; monitoring of serum concentrations is necessary. The safety in pregnant women is unclear, so it should only be administered when the therapeutic benefits outweigh the risks. In pediatric patients, electrolyte regulation may be impaired, so serum electrolyte levels should be closely monitored, and rapid administration should be avoided, especially in low-birth-weight infants. Elderly patients may have decreased physiological functions, so care should be taken to administer the medication slowly and adjust dosages as necessary. If the solution is not clear or if the seal is broken, it should not be used, and as the solution is concentrated, it should be appropriately diluted before injection. Calcium and phosphate can precipitate each other; thus, when administering phosphates to patients requiring them, caution should be exercised, and potassium content should be combined with other medications for total potassium management.

Side effects

anaphylaxis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container that prevents air and moisture access. The recommended storage temperature is between 1 and 30 degrees Celsius (room temperature). Proper storage will ensure the medication's efficacy is preserved.

Appearance and packaging

Appearance

A colorless, transparent solution contained in a polypropylene container.

Package unit

20 milliliters x 50

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.